Trial Profile

A Phase 1b/2a study assessing IM-250 in treatment of Herpes simplex.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IM-250 (Primary)
Indications Herpes simplex virus infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

23 Jun 2025 New trial record
07 Jun 2025 According to Innovative Molecules media release, Topline results from the Phase 1b portion of the study are expected in H2, 2025.
07 Jun 2025 According to Innovative Molecules media release, company announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus (HSV).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com